These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

619 related articles for article (PubMed ID: 34739424)

  • 1. Decreased Systemic Busulfan Exposure After Oral Dosing With Concomitant Levetiracetam Compared With Phenytoin.
    Artul T; Henig I; Nassar L; Yehudai-Ofir D; Scherb I; Lurie Y; Efrati E; Zuckerman T; Kurnik D
    Ther Drug Monit; 2022 Jun; 44(3):414-418. PubMed ID: 34739424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of levetiracetam versus phenytoin/fosphenytoin for busulfan seizure prophylaxis at a pediatric institution.
    Hughes K; Garrity L; Nelson AS; Lane A; Teusink-Cross A
    Pediatr Transplant; 2021 Jun; 25(4):e14026. PubMed ID: 33894096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levetiracetam for the prevention of busulfan-induced seizures in pediatric hematopoietic cell transplantation recipients.
    Floeter AE; McCune JS
    J Oncol Pharm Pract; 2017 Jul; 23(5):344-349. PubMed ID: 27208016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of levetiracetam with phenytoin for the prevention of intravenous busulfan-induced seizures in hematopoietic cell transplantation recipients.
    Akiyama K; Kume T; Fukaya M; Shiki I; Enami T; Tatara R; Shino M; Ikeda T
    Cancer Chemother Pharmacol; 2018 Oct; 82(4):717-721. PubMed ID: 30083882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral levetiracetam for prevention of busulfan-induced seizures in adult hematopoietic cell transplant.
    Chaguaceda C; Aguilera-Jiménez V; Gutierrez G; Roura J; Riu G
    Int J Clin Pharm; 2020 Apr; 42(2):351-354. PubMed ID: 32026356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The pharmacokinetics and pharmacodynamics of busulfan when combined with melphalan as conditioning in adult autologous stem cell transplant recipients.
    Willcox A; Wong E; Nath C; Janson B; Harrison SJ; Hoyt R; Bajel A; Shaw P; Ritchie D; Grigg A
    Ann Hematol; 2018 Dec; 97(12):2509-2518. PubMed ID: 30051172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence on Busilvex pharmacokinetics of clonazepam compared to previous phenytoin historical data.
    Carreras E; Cahn JY; Puozzo C; Kröger N; Sanz G; Buzyn A; Bacigalupo A; Vernant JP
    Anticancer Res; 2010 Jul; 30(7):2977-84. PubMed ID: 20683042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of an Oral Busulfan Test Dose in Patients Undergoing Hematopoietic Stem Cell Transplantation Treated With or Without Fludarabine.
    de Castro FA; Simões BP; Godoy AL; Bertagnoli Trigo FM; Coelho EB; Lanchote VL
    J Clin Pharmacol; 2016 Dec; 56(12):1555-1562. PubMed ID: 27130252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes.
    Russell JA; Tran HT; Quinlan D; Chaudhry A; Duggan P; Brown C; Stewart D; Ruether JD; Morris D; Glick S; Gyonyor E; Andersson BS
    Biol Blood Marrow Transplant; 2002; 8(9):468-76. PubMed ID: 12374451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GSTA1 Genetic Variants and Conditioning Regimen: Missing Key Factors in Dosing Guidelines of Busulfan in Pediatric Hematopoietic Stem Cell Transplantation.
    Nava T; Rezgui MA; Uppugunduri CRS; Curtis PH; Théoret Y; Duval M; Daudt LE; Ansari M; Krajinovic M; Bittencourt H
    Biol Blood Marrow Transplant; 2017 Nov; 23(11):1918-1924. PubMed ID: 28807770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality.
    Kashyap A; Wingard J; Cagnoni P; Roy J; Tarantolo S; Hu W; Blume K; Niland J; Palmer JM; Vaughan W; Fernandez H; Champlin R; Forman S; Andersson BS
    Biol Blood Marrow Transplant; 2002; 8(9):493-500. PubMed ID: 12374454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Cyclophosphamide Combined with Total Body Irradiation, Oral Busulfan, or Intravenous Busulfan for Allogeneic Hematopoietic Cell Transplantation in Adults with Acute Lymphoblastic Leukemia.
    Mitsuhashi K; Kako S; Shigematsu A; Atsuta Y; Doki N; Fukuda T; Kanamori H; Onizuka M; Takahashi S; Ozawa Y; Kurokawa M; Inoue Y; Nagamura-Inoue T; Morishima Y; Mizuta S; Tanaka J;
    Biol Blood Marrow Transplant; 2016 Dec; 22(12):2194-2200. PubMed ID: 27638362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematopoietic stem cell transplantation.
    Ansari M; Théoret Y; Rezgui MA; Peters C; Mezziani S; Desjean C; Vachon MF; Champagne MA; Duval M; Krajinovic M; Bittencourt H;
    Ther Drug Monit; 2014 Feb; 36(1):93-9. PubMed ID: 24061446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal regimen of levetiracetam for prevention of busulfan-induced seizure in patients undergoing hematopoietic stem cell transplantation: A review of available evidence.
    Tavajohi R; Shahrami B; Rostami T; Kiumarsi A; Honarmand H; Hadjibabaie M
    J Oncol Pharm Pract; 2023 Jun; 29(4):927-933. PubMed ID: 36843563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levetiracetam for busulfan-induced seizure prophylaxis in children undergoing hematopoietic stem cell transplantation.
    Soni S; Skeens M; Termuhlen AM; Bajwa RP; Gross TG; Pai V
    Pediatr Blood Cancer; 2012 Oct; 59(4):762-4. PubMed ID: 22378696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of clonazepam and levetiracetam in children for prevention of busulfan-induced seizure in hematopoietic stem cell transplantation.
    Tsujimoto SI; Shirai R; Utano T; Osumi T; Matsumoto K; Shioda Y; Kiyotani C; Uchiyama T; Deguchi T; Terashima K; Tomizawa D; Matsumoto K; Kato M
    Int J Hematol; 2020 Mar; 111(3):463-466. PubMed ID: 31863341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lorazepam for seizure prophylaxis during high-dose busulfan administration.
    Chan KW; Mullen CA; Worth LL; Choroszy M; Koontz S; Tran H; Slopis J
    Bone Marrow Transplant; 2002 Jun; 29(12):963-5. PubMed ID: 12098063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia.
    Pidala J; Kim J; Anasetti C; Kharfan-Dabaja MA; Nishihori T; Field T; Perkins J; Perez L; Fernandez HF
    J Hematol Oncol; 2010 Oct; 3():36. PubMed ID: 20925957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic drug monitoring-guided dosing of busulfan differs from weight-based dosing in hematopoietic stem cell transplant patients.
    Salman B; Al-Za'abi M; Al-Huneini M; Dennison D; Al-Rawas A; Al-Kindi S; Al-Farsi K; Tauro M; Al-Khabori M
    Hematol Oncol Stem Cell Ther; 2017 Jun; 10(2):70-78. PubMed ID: 28408108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Home administration of high-dose oral busulfan in patients undergoing hematopoietic stem cell transplantation.
    Matthews RH; Emami M; Connaghan DG; Holland HK; Morris LE
    Bone Marrow Transplant; 2007 Apr; 39(7):397-400. PubMed ID: 17322933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.